Leqembi™ and Kisunla™ Treatment Program for Private Patients

Following recent MHRA approval, we are delighted to inform you that both Leqembi™and Kisunla™will be available at Re:Cognition Health’s (RCH’s) centres in London and Bristol. As you are aware, Leqembi™and Kisunla™, a monoclonal antibody (MAB), has demonstrated efficacy, in the phase 3 Clarity global clinical trial, for effective removal of toxic amyloid protein from the brain, correlated with slowing the progression of Alzheimer’s disease and its symptoms. Please see reference to NEJM Nov 2022 here.

Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: https://www.leqembi.com/en

https://kisunla.lilly.com/

Re:Cognition Health – the most experienced provider in the field

Re:Cognition Health’s physicians have extensive experience with both Leqembi™and Kisunla™, having treated patients for years in the clinical trials. With more experience than any other provider in the UK in treating patients with Leqembi™, we have administered over 2,033 Leqembi™ treatments and more than 9,000 IV infusions, within clinical trials, for other new medications of the same class as Leqembi™,  our clinical team is uniquely qualified to carefully monitor the delivery of this new therapy in the UK.

It is acknowledged that monoclonal antibodies against brain amyloid protein, including  Leqembi™and Kisunla™ have recognised potential side effects, particularly Amyloid Related Imaging Abnormalities (ARIA). At RCH, our expert neuroradiologists have extensive (over a decade) experience diagnosing ARIA in clinical trials. Therefore, only individuals meeting specific criteria, such as those without APOE 4/4, ARIA E, more than four micro haemorrhages on MRI, or anticoagulant use, will be eligible.

This approval marks an historic breakthrough as Leqembi™ is the first drug in the UK approved to address the underlying cause of Alzheimer’s Disease, and most recently, Kisunla™ has also been approved.

Currently we are delighted to offer eligibility assessments for patients seeking treatment with Leqembi™and Kisunla™via RCH’s Private Treatment Program.

Additional Information:

• Eligibility: Confirmation of elevated amyloid protein by Amyloid PET or CSF analysis is mandatory.
• Treatment: Bi-weekly intravenous infusion of Leqembi™, monthly intravenous infusion of Kisunla™, with monitoring for both via MRI scans
• Required: A study program partner (family member or friend) for regular contact.
• Follow-Up: Recommended amyloid re-assessment at 12 months, then at 18 or 24 months.